Cancer Clinical Trials & Investigational Treatments Center
The UCSF Cancer Clinical Trials and Investigational Treatments Center offers patients with advanced cancer the opportunity to participate in the trials testing new, cutting-edge treatments for the first time in humans. These studies are known as early phase, or phase I, clinical trials. Our center is open to patients with solid tumor cancers, including breast, pancreatic, colorectal, prostate, lung and gynecologic cancers.
Our program brings together leading physician-scientists and other researchers who are at work on more effective, less toxic cancer treatments. These may be new medications; novel treatment combinations; or innovative approaches, such as targeted therapies that attack the tumor without damaging healthy cells. Patients who volunteer for these clinical trials may be the first to benefit from a pioneering therapy.
Our program is part of the UCSF Helen Diller Family Comprehensive Cancer Center, which the National Cancer Institute has designated a comprehensive cancer center since 1999. This designation recognizes centers committed to both pursuing needed research and providing full services to patients with cancer. As such a center, we have numerous early phase clinical trials that are recruiting patients with advanced cancers.
While our center is currently limited to early phase trials, UCSF has a robust clinical trials program that includes later phase studies in most types of cancer. To learn about available trials, please call (877) 827-3222, email [email protected] or search our database of clinical cancer trials at UCSF.
Pilot Study of Pancreatic Cancer Screening
Proportion of participants with an abnormal MRI finding will be reported as an event. An estimated event rate of 19% in participants with a strong family history (FH) of pancreatic cancer and 10% in those participants without a st...
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor P...
Will be defined as the proportion of participants randomized to that arm whose status is stable disease (SD) or better (complete response (CR), partial response (PR)). The observed ORR will be compared to the respective null (inef...
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostat...
A minimum of 3 patients will be treated at each dose level. If < 33%of patients (i.e. 0 of 3 patients, or 1 of 6 patients) within a cohort have a dose-limiting toxicity (DLT in Cycle 1, then enrollment of the next cohort may comme...
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation ...
Adverse events, serious adverse events, and dose limiting toxicities
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prost...
The composite response rate is determined by a combination of a decline from baseline in serum PSA of >= 50%, confirmed by repeat measurement ≥ 4 weeks later (PSA50) AND/OR a complete response (CR) or partial response (PR) as dete...
A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
Using PARADIGM and DiPSC tools, we will discover the expression and clinical factors that are predictive and correlate with treatment benefit within each treatment cohort.
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...
Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Adv...
Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline
Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in ...
A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related
Awards & recognition
Best hospital in Northern California
Best in Northern California in cancer care
Accreditations & memberships
National Cancer Institute
The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.
Commission on Cancer
UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.
National Comprehensive Cancer Network
UCSF is a founding member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes
Our research initiatives
Athena Breast Health Network
The Athena Breast Health Network, a collaborative organization that includes UCSF, promotes data sharing to help all partners deliver more effective and personalized care to patients with breast cancer.
Breast Cancer Trials
BreastCancerTrials.org helps match patients who want to participate in breast cancer research with open studies that are right for them.
UCSF Helen Diller Family Comprehensive Cancer Center Research
UCSF is home to a range of research initiatives aimed at improving outcomes for cancer patients everywhere. This includes research on topics such as immunotherapy, BRCA mutations and molecular diagnostic testing.